References
- 1. Poux JM, Cadranel JF, Fievet P, Dumouchel P, Collot G. Measurement of gamma glutamyl transpeptidase activity: A useful and low-cost tool for the detection of HCV infection in haemodialysed patients. Nephrol Dial Transplant. 1998;13(5):1324. DOI: 10.1093/oxfordjournals.ndt.a02788610.1093/oxfordjournals.ndt.a027886
- 2. Pereira BJ, Levery AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 1997;51(4):981-999. DOI: 10.1038/ki.1997.13910.1038/ki.1997.139
- 3. Weber D, Rutala W, Fried M. Hepatitis C Virus Outbreaks in Hemodialysis Centers: A Continuing Problem. Infection Control & Hospital Epidemiology. 2016;37(2):140-142. DOI: 10.1017/ice.2015.31110.1017/ice.2015.311
- 4. Grigorescu M. HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C. J Gastrointestin Liver Dis. 2009;18(1):45-50.
- 5. Nițescu M, Vâjâitu C, Săndulescu O, Streinu-Cercel A, Pițigoi D, Preoțescu LL, et al. Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals. Rev Romana Med Lab. 2017;25(4):355-63. DOI: 10.1515/rrlm-2017-003010.1515/rrlm-2017-0030
- 6. Chen QW, Cheng CS, Chen H, Ning ZY, Tang SF, Zhang X, et al. Effectiveness and complications of ultrasound guided fine needle aspiration for primary liver cancer in a Chinese population with serum α-fetoprotein levels ≤200 ng/ml - A study based on 4,312 patients. PLoS One. 2014;9(8) :e101536. DOI: 10.1371/journal.pone.0101536
- 7. Dzekova-Vidimliski P, Dzikova S, Selim G, Gelev S, Trajceska L, Pushevski V, Sikole A. Ultrasound predictors of compensated liver cirrhosis in hemodialysis patients with hepatitis C. Saudi J Kidney Dis Transpl. 2013;24(1):30-35. DOI: 10.4103/1319-2442.10623510.4103/1319-2442.106235
- 8. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraob-server variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614-2618. DOI: 10.1111/j.1572-0241.2002.06038.x
- 9. Orasan OH, Orasan RA, Patiu IM, Dumitrascu DL. Hyaluronic acid in end-stage renal disease treated by hemodialysis. Ren Fail. 2015;37(9):1531-1532. DOI: 10.3109/0886022X.2015.107731210.3109/0886022X.2015.1077312
- 10. Orasan OH, Urian L, Ciulei G, et al. Thrombocytopenia in end-stage renal disease and chronic viral hepatitis B or C. J Mind Med Sci. 2018;5(2):236-243. DOI: 10.22543/7674.52.P236243
- 11. Jiang Y, Huang E, Mehrnia A, Kamgar M, Pham PT, Ogunorunyinka O, et al. Can aminotransferase-to-platelet ratio index and other non-invasive markers effectively reduce liver biopsies for renal transplant evaluation of hepatitis C virus-positive patients? Nephrol Dial Transplant. 2014;29(6):1247-1252. DOI: 10.1093/ndt/gft48510.1093/ndt/gft485
- 12. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol. 2006;44(3):462-474. DOI: 10.1016/j.jhep.2005.10.01910.1016/j.jhep.2005.10.019
- 13. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835-847. DOI: 10.1016/j.jhep.2008.02.00810.1016/j.jhep.2008.02.008
- 14. Liu CH, Liang CC, Huang KW, Liu CJ, Chen SI, Lin JW, et al. Transient Elastography to Assess Hepatic Fibrosis in Hemodialysis Chronic Hepatitis C Patients. Clin J Am Soc Nephrol. 2011;6(5):1057-1065. DOI: 10.2215/CJN.0432051010.2215/CJN.04320510
- 15. Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, et al. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation. 2005;80(11):1550-1555. DOI: 10.1097/01.tp.0000183399.85804.0210.1097/01.tp.0000183399.85804.02
- 16. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2011;357(9262):1069-1075. DOI: 10.1016/S0140-6736(00)04258-610.1016/S0140-6736(00)04258-6
- 17. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343-350. DOI: 10.1053/j.gastro.2004.11.01810.1053/j.gastro.2004.11.018
- 18. Mikolasevic I, Orlic L, Zaputovic L, Racki S, Cubranic Z, Anic K, et al. Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease. Wien Klin Wochenschr. 2015;127(11-12):451-458. DOI: 10.1007/s00508-015-0757-z10.1007/s00508-015-0757-z
- 19. Canbakan M, Senturk H, Canbakan B, et al. Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C. Nephron Clin Pract. 2011;117(3):289-296. DOI: 10.1159/00032075110.1159/000320751
- 20. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS-medicine. 2009;6(7):e1000097. DOI: 10.1371/journal.pmed.1000097
- 21. Moradi H, Said HM, Vaziri ND. Post-transcriptional nature of uremia-induced downregulation of he-patic apolipoprotein A-I production. Transl Res. 2013;161(6):477-485. DOI: 10.1016/j.trsl.2012.11.00110.1016/j.trsl.2012.11.001
- 22. Pruijm M, Schmidtko J, Aho A, Pagano S, Roux-Lombard P, Teta D, et al. High Prevalence of Anti-Apolipoprotein/A-1 Autoantibodies in Maintenance Hemo-dialysis and Association With Dialysis Vintage. Ther Apher Dial. 2012;16(6):588-594. DOI: 10.1111/j.1744-9987.2012.01102.x10.1111/j.1744-9987.2012.01102.x
- 23. Rolla R, De Mauri A, Valsesia A, Vidali M, Chiarinotti D, Bellomo G. Lipoprotein profile, lipoprotein-associated phospholipase A2 and cardiovascular risk in hemodialysis patients. J Nephrol. 2015;28(6):749-755. DOI: 10.1007/s40620-015-0194-010.1007/s40620-015-0194-0
- 24. Calabresi L, Simonelli S, Conca P, et al. Acquired leci-thin: Cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. J Intern Med. 2015;277(5):552-561. DOI: 10.1111/joim.1229010.1111/joim.12290
- 25. Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res. 2009;153(2):77-85. DOI: 10.1016/j.trsl.2008.11.00710.1016/j.trsl.2008.11.007
- 26. Pahl MV, Ni Z, Sepassi L, Moradi H, Vaziri ND. Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD). Nephrol Dial Transplant. 2009;24(8):2541-2546. DOI: 10.1093/ndt/gfp120
- 27. Kaysen GA, Dalrymple LS, Grimes B, Chertow GM, Kornak J, Johansen KL. Changes in serum inflammatory markers are associated with changes in apolipoprotein A1 but not B after the initiation of dialysis. Nephrol Dial Transplant. 2014;29(2):430-437. DOI: 10.1093/ndt/gft37010.1093/ndt/gft370
- 28. Honda H, Hirano T, Ueda M, Kojima S, Mashiba S, Hayase Y, et al. High-Density Lipoprotein Subfractions and Their Oxidized Subfraction Particles in Patients with Chronic Kidney Disease. J Atheroscler Thromb. 2016;23(1):81-94. DOI: 10.5551/jat.3001510.5551/jat.30015
- 29. Ribeiro S, do Sameiro Faria M, Mascarenhas-Melo F, Freitas I, Mendonça MI, Nascimento H, et al. Main determinants of PON1 activity in hemodialysis patients. Am J Nephrol. 2012;36(4):317-323. DOI: 10.1159/00034223510.1159/000342235
- 30. Kimak E, Hałabiś M, Baranowicz-Gąszczyk I, Solski J, Książek A. Association between moderately oxidized low-density lipoprotein and high-density lipo-protein particle subclass distribution in hemodialyzed and post-renal transplant patients. J Zhejiang Univ Sci B.2011;12(5):365-371. DOI: 10.1631/jzus.B100034810.1631/jzus.B1000348
- 31. Lokesh S, Kadavanu TM,Green SR, et al. A Comparative Study of Lipid Profile and Cardiovascular Risk Biomarkers Among Chronic Haemodialysis Patients and Healthy Individuals. J Clin Diagnostic Res. 2016;10(9):36-40. DOI: 10.7860/JCDR/2016/21897.852310.7860/JCDR/2016/21897.8523
- 32. Ikewaki K. In vivo kinetic studies to further understand pathogenesis of abnormal lipoprotein metabolism in chronic kidney disease. Clin Exp Nephrol. 2014;18(2):261-264. DOI: 10.1007/s10157-013-0881-x10.1007/s10157-013-0881-x
- 33. Yeo Y, Byun SW, Lee JY, Min WK, Park JS, Kim SB. Lack of association between small dense low-density lipoprotein levels and coronary artery disease in chronic hemodialysis patients. Am J Nephrol. 2009;30(3):310-314. DOI: 10.1159/00022593910.1159/000225939
- 34. Samouilidou EC, Grapsa E. Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis. Ren Fail. 2008;30(7):711-715. DOI: 10.1080/0886022080221297310.1080/08860220802212973
- 35. Wu S, Chen X, Yuan S, Peng D, Zhou A, Li J. Impaired cholesterol efflux capacity is related to increased carotid intima media thickness in patients with end-stage renal disease. Int J Cardiol. 2015;187(1):456-458. DOI: 10.1016/j.ijcard.2015.03.36210.1016/j.ijcard.2015.03.362
- 36. Moradi H, Said HM, Vaziri ND. Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production. Transl Res. 2013;161(6):477-485. DOI: 10.1016/j.trsl.2012.11.00110.1016/j.trsl.2012.11.001
- 37. Holzer M, Birner-Gruenberger R, Stojakovic T, et al. Uremia Alters HDL Composition and Function. J Am Soc Nephrol. 2011;22(9):1631-1641. DOI: 10.1681/ASN.201011114410.1681/ASN.2010111144
- 38. Boon AC, Bulmer AC, Coombes JS, Fassett RG. Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. AJP Ren Physiol. 2014;307(2):F123-136. DOI: 10.1152/ajprenal.00039.201410.1152/ajprenal.00039.2014
- 39. Mekki K, Taleb W, Bouzidi N, Kaddous A, Bouchenak M. Effect of hemodialysis and peritoneal dialysis on redox status in chronic renal failure patients: a comparative study. Lipids Health Dis. 2010;9:93. DOI: 10.1186/1476-511X-9-9310.1186/1476-511X-9-93
- 40. Si X, Li J, Bi X, Wu L, Wu X. Clinical evaluation of high-volume hemofiltration with hemoperfusion followed by intermittent hemodialysis in the treatment of acute wasp stings complicated by multiple organ dys-function syndrome. PLoS One. 2015;10(7):1-11. DOI: 10.1371/journal.pone.013270810.1371/journal.pone.0132708
- 41. Tbahriti HF, Kaddous A, Bouchenak M, Mekki K. Effect of Different Stages of Chronic Kidney Disease and Renal Replacement Therapies on Oxidant-Anti-oxidant Balance in Uremic Patients. Biochem Res Int. 2013;2013:1-6. DOI: 10.1155/2013/35898510.1155/2013/358985
- 42. Zhang L, Yang Y, Tang Y, Zhao Y, Cao Y, Su B, et al. Recovery from AKI following multiple wasp stings: A case series. Clin J Am Soc Nephrol. 2013;8(11):1850-1856. DOI: 10.2215/CJN.1208111210.2215/CJN.12081112
- 43. Cheng YC, Kuo WW, Wu CH, Shu WT, Kuo CH, Hwang JM, et al. Iron status and cardiovascular risk factors in patients with haemodialysis versus patients with ischaemic heart disease. Nephrol. 2009;14(1):65-69. DOI: 10.1111/j.1440-1797.2008.01004.x10.1111/j.1440-1797.2008.01004.x
- 44. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat. 2002;9(2):128-133. DOI: 10.1046/j.1365-2893.2002.00341.x10.1046/j.1365-2893.2002.00341.x
- 45. Bacq Y, Schillio Y, Brechot JF, De Muret A, Dubois F, Metman EH. Decrease of haptoglobin serum level in patients with chronic viral hepatitis C. Gastroenterol Clin Biol. 1993;17(5):364-369.
- 46. Trznadel K, Luciak M, Paradowski M, Kubasiewicz-Ujma B. Hemodialysis and the acute-phase response in chronic uremic patients. Int J Artif Organs. 1989;12(12):762-765. DOI: 10.1177/03913988890120120510.1177/039139888901201205
- 47. Argilés A, Kerr PG, Mourad G, Mion CM, Atkins RC. Serum alpha 2-macroglobulin in haemodialysis patients: baseline and kinetic studies. Nephrol Dial Transpl. 1993;8(10):1118-1123.
- 48. Petrauskiene V, Vaiciuniene R, Kuzminskis V, Ziginskiene E, Grazulis S, Jonaitiene E, et al. Associations of vascular calcification, calcium phosphate disturbances, FGF 23 and Matrix Gla protein with mortality of hemodialysis patients: one center cohort study. Rev Romana Med Lab. 2018;26(4):451-60. DOI:10.2478/rrlm-2018-0034. DOI: 10.2478/rrlm-2018-003410.2478/rrlm-2018-0034.DOI:10.2478/rrlm-2018-0034
- 49. Maor Y, Calès P, Bashari D, et al. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia. 2007;13(6):722-729. DOI: 10.1111/j.1365-2516.2007.01548.x10.1111/j.1365-2516.2007.01548.x
- 50. Lin YP, Yang CY, Liao CC, Yu WC, Chi CW, Lin CH. Plasma protein characteristics of long-term hemodialysis survivors. PLoS One. 2012;7(7):e40232. DOI: 10.1371/journal.pone.0040232
- 51. Fabrizi F, de Vecchi AF, Qureshi AR, et al. Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population. Int J Artif Organs. 2007;30(1):6-15. DOI: 10.1177/03913988070300010310.1177/039139880703000103
- 52. Souza JF, Longui CA, Miorin LA, Sens YA. Gamma-Glutamyltransferase Activity in Chronic Dialysis Patients and Renal Transplant Recipients With Hepatitis C Virus Infection. Transplant Proc. 2008;40(5):1319-1323. DOI: 10.1016/j.transproceed.2008.03.15710.1016/j.transproceed.2008.03.157
- 53. Liberato I, Lopes E, Cavalcante M, Pinto T, Moura I, Loureiro-Jr L. Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis. Clinics. 2012;67(2):131-134. DOI: 10.6061/clinics/2012(02)0710.6061/clinics/2012(02)07